IPCA surges after string of broker upgrades

Tags: Ipca, Companies
Shares of IPCA Laboratories Ltd gain 4 per cent to Rs 861.30 after Morgan Stanley initiates coverage on the company with a "buy" rating and a target price of Rs 1,101, calling it its "preferred healthcare mid-cap stock."

Morgan Stanley says that IPCA's growing India business, ramp-up in anti-malaria drugs and increased capacity for the U.S. market should drive 23 percent compounded annual growth in earnings until fiscal 2016, versus an average 16.3 percent for other Indian healthcare stocks in its coverage.

IPCA has received a slew of recent upgrades from foreign banks, highlighting its improving outlook. Shares are up 18.7 percent so far this year, compared with a 3.3 percent gain in the BSE healthcare index and a 3 percent rise in the BSE Sensex.

Last month, Credit Suisse initiated coverage on IPCA with an "outperform" rating, while CLSA upgraded the stock in January to "buy" from "outperform.

RELATED ARTICLES

EDITORIAL OF THE DAY

  • The solution to tackling recurrent droughts is in managing consumption of water, not its overuse

    A staggering 33 crore people or more than a quarter of the country’s population are in the grip of drought and consequently, face drinking water sho

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Tushar Gandhi

An unexplored side of rural enterprise

What is rural enterprise? Ask this qu­estion and 9 out ...

Kuruvilla Pandikattu

Black and white of morality

Would you kill one innocent person to save five? Choose ...

Shona Adhikari

Let's head to Bangalore & catch up on art

Bangalore art scene is bang in the middle of news, ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture